Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. ADR (NQ: NBTX )

5.300 -0.060 (-1.12%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. ADR

< Previous 1 2 3 4 5 Next >
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix S.A. (NASDAQ: NBTX) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST 
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society... 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
Reported €30.2 million in cash and cash equivalents as of March 31, 2023 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
Company agreed to term sheet as of May 3, 2023 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.